Key facts
- This page summarizes David A. Rosa's Form 4 filing for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Apr 2025, 16:34.
David A. Rosa - 17 Apr 2025 Form 4 Insider Report for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- NMTC
- Reported as of
- 17 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2025, 16:34:52 UTC
- Prior SEC filing
- 07 Apr 2025
- Next SEC filing
- 02 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephanie Swan, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David A. Rosa filed Form 4 for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) on 21 Apr 2025.
Change
- Previous filing in this sequence was filed on 07 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NMTC
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +750,000
- Change %
- Price
- $0.000000
- Shares after
- 750,000
- Date
- 17 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750,000
- Exercise price
- $0.5796
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments.